Exclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio

Lei Lei Wu

News Reporter

Eli Lilly is adding three new preclinical candidates to its immune and inflammatory medicines armory through TRexBio, a Bay Area biotech that specializes in T …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Exclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio

Lei Lei Wu

News Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

HHS can require approval for drugmakers to apply 340B rebate models, court rules

Ex­clu­sive: Eli Lil­ly boosts in­flam­ma­to­ry dis­ease pipeline, li­cens­es three can­di­dates from TRexBio

News Reporter

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Exclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio